BioSpace News Archive

Covalon Technologies Ltd., an advanced medical technologies company, announced its fiscal 2022 fourth quarter and year end results for the period ended September 30, 2022.

Paragon 28, Inc. announced the pricing of the previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions.

Oxurion NV announced that it has further amended its mandatory convertible bonds issuance and subscription agreement with the Negma Group.

Immuron Limited today announces that a response letter has been submitted to the US Food and Drug Administration (FDA). Immuron has previously reported feedback was received from the FDA following a review of the Investigational New Drug (IND) application (ASX announcement July 26, 2022) of a new oral therapeutic targeting Campylobacter and ETEC developed in collaboration with Immuron.

KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics ® Platform Technology.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations.

Vaginal discomfort is one of the leading reasons women seek healthcare advice, and over 90% of these cases can be attributed to imbalances in the vaginal microbiome.

Myosana Therapeutics, Inc. today announced the completion of a seed funding round totaling over $5 million led by investor John Ballantyne, Ph.D.

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced that the U.S. Food and Drug Administration (FDA) approved ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use for the treatment of house dust mite (HDM)-induced allergic rhinitis in persons ages 12 through 17.

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”) announced today that its board of directors has resolved on pursuing a restructuring plan which involves transferring its pharmaceutical activities to a new wholly owned subsidiary.